HDAC Histone deacetylases

HDAC (Histone deacetylases) are a class of enzymes that remove acetyl groups (O=C-CH3) from an ε-N-acetyl lysine amino acid on ahistone, allowing the histones to wrap the DNA more tightly. This is important because DNA is wrapped around histones, and DNA expression is regulated by acetylation and de-acetylation. Its action is opposite to that of histone acetyltransferase. HDAC proteins are now also called lysine deacetylases (KDAC), to describe their function rather than their target, which also includes non-histone proteins. Together with the acetylpolyamine amidohydrolases and the acetoin utilization proteins, the histone deacetylases form an ancient protein superfamily known as the superfamily.

www.MedChemExpress.com 1 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] HDAC Inhibitors, Antagonists, Activators & Modulators

1-Naphthohydroxamic acid 4-Phenylbutyric acid Cat. No.: HY-130538 (4-PBA; Benzenebutyric acid) Cat. No.: HY-A0281

1-Naphthohydroxamic acid (Compound 2) is a potent 4-Phenylbutyric acid (4-PBA) is an inhibitor of and selective HDAC8 inhibitor with an IC50 of 14 HDAC and endoplasmic reticulum (ER) stress, used μM. 1-Naphthohydroxamic acid is more selectively in cancer and infection research. for HDAC8 than class I HDAC1 and class II HDAC6

(IC50 >100 μM).

Purity: ≥98.0% Purity: 99.98% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 500 mg, 5 g

Abexinostat Ac-Arg-Gly-Lys(Ac)-AMC (CRA 024781; PCI-24781) Cat. No.: HY-10990 Cat. No.: HY-P2462

Abexinostat (CRA 024781) is a novel pan-HDAC Ac-Arg-Gly-Lys(Ac)-AMC is a substrate for HDAC. inhibitor mostly targeting HDAC1 with Ki of 7 nM.

Purity: 98.61% Purity: >98% Clinical Data: Phase 3 Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

Ac-Lys-AMC ACY-1083 Cat. No.: HY-128919 Cat. No.: HY-111791

Ac-Lys-AMC (Hexanamide), also termed MAL, is a ACY-1083 is a selective and brain-penetrating fluorescent substrate for histone deacetylase HDAC6 inhibitor with an IC50 of 3 nM and is HDACs. 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses -induced peripheral neuropathy. Purity: >98% Purity: 99.43% Clinical Data: Clinical Data: No Development Reported Size: 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ACY-738 ACY-775 Cat. No.: HY-19327 Cat. No.: HY-19328

ACY-738 is a potent, selective and ACY-775 is a potent and selective inhibitor of the orally-bioavailable HDAC6 inhibitor, with an IC50 of histone deacetylase 6 (HDAC6) with an IC50 of of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and 7.5nM.

HDAC3, with IC50s of 94, 128, and 218 nM.

Purity: 98.75% Purity: 99.83% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ACY-957 AES-135 Cat. No.: HY-104008 Cat. No.: HY-114483

ACY-957 is an orally active and selective AES-135, a hydroxamic acid-based HDAC inhibitor, inhibitor of HDAC1 and HDAC2, with IC50s of 7 prolongs survival in an orthotopic mouse model of nM, 18 nM, and 1300 nM against HDAC1/2/3, . AES-135 inhibits HDAC3, HDAC6, respectively, and shows no inhibition on HDAC8, and HDAC11 with IC50s ranging from 190-1100 HDAC4/5/6/7/8/9. nM.

Purity: 99.91% Purity: 98.31% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

www.MedChemExpress.com 3

Alteminostat (CKD-581) Cat. No.: HY-109109 (OSI 2040) Cat. No.: HY-N6735

Alteminostat (CKD-581) is a potent HDAC Apicidin (OSI 2040) is a fungal metabolite, acts inhibitor. Alteminostat inhibits the class I-II as a histone deacetylase (HDAC) inhibitor, with HDAC family via histone H3 and tubulin antiparasitic activity and a broad spectrum acetylation. Alteminostat can be used for lymphoma antiproliferative activity. and multiple myeloma research.

Purity: >98% Purity: ≥99.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg

Belinostat BG45 (PXD101; PX105684) Cat. No.: HY-10225 Cat. No.: HY-18712

Belinostat (PXD101; PX105684) is a potent HDAC BG45 is an HDAC class I inhibitor with selectivity

inhibitor with an IC50 of 27 nM in HeLa cell for HDAC3 (IC50 = 289 nM). It inhibits HDAC1, extracts. HDAC2, and HDAC6 with greatly reduced potency (IC50s = 2, 2.2, and >20 μM, respectively).

Purity: 99.94% Purity: 99.95% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BML-210 BRD 4354 Cat. No.: HY-19350 Cat. No.: HY-112719

BML-210 is a novel HDAC inhibitor, and its BRD 4354 is a moderately potent inhibitor of

mechanism of action has not been characterized. HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively.

Purity: 96.38% Purity: 98.29% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BRD 4354 ditrifluoroacetate BRD-6929 Cat. No.: HY-112719B Cat. No.: HY-100719

BRD 4354 (ditrifluoroacetate) is a moderately BRD-6929 is a potent, selective

potent inhibitor of HDAC5 and HDAC9, with IC50s brain-penetrant inhibitor of class I histone

of 0.85 and 1.88 μM, respectively. deacetylase HDAC1 and HDAC2 inhibitor with IC50 of 1 nM and 8 nM, respectively.

Purity: 98.06% Purity: 99.55% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, Size: 10 mM × 1 mL, 1 mg, 5 mg

BRD3308 BRD73954 Cat. No.: HY-19618 Cat. No.: HY-18700

BRD3308 is a highly selective HDAC3 inhibitor BRD73954 ia a potent and selective HDAC inhibitor

with an IC50 of 54 nM. BRD3308 is 23-fold with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8,

selectivity for HDAC3 over HDAC1 (IC50 of 1.26 respectively.

μM) or HDAC2 (IC50 of 1.34 μM).

Purity: 95.94% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Bufexamac CAY10603 (Bufexamic acid) Cat. No.: HY-B0494 (BML-281) Cat. No.: HY-18613

Bufexamac is a class IIB histone deacetylases CAY10603 (BML-281) is a potent and selective

(HDAC6 and HDAC10) inhibitor used as an HDAC6 inhibitor, with an IC50 of 2 pM; CAY10603 anti-inflammatory agent. (BML-281) also inhibits HDAC1, HDAC2, HDAC3,

HDAC8, HDAC10, with IC50s of 271, 252, 0.42, 6851, 90.7 nM.

Purity: ≥98.0% Purity: 95.39% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg, 500 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CG-200745 CG347B Cat. No.: HY-16138 Cat. No.: HY-135890

CG-200745 is a potent HDAC inhibitor which has CG347B is a selective HDAC6 inhibitor. the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. CG200745 inhibits deacetylation of histone H3 and tubulin. CG200745 induces .

Purity: >98% Purity: 98.84% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg

CHDI-390576 Chlamydocin Cat. No.: HY-119939 Cat. No.: HY-P2228

CHDI-390576, a potent, cell permeable and CNS Chlamydocin, a fungal metabolite, is a highly penetrant class IIa histone deacetylase (HDAC) potent HDAC inhibitor, with an IC50 of 1.3 nM. inhibitor with IC50s of 54 nM, 60 nM, 31 nM, 50 nM Chlamydocin exhibits potent antiproliferative and for class IIa HDAC4, HDAC5, HDAC7, HDAC9, anticancer activities. Chlamydocin induces respectively, shows >500-fold selectivity over apoptosis by activating caspase-3. class I HDACs (1, 2, 3) and ~150-fold… Purity: ≥98.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

Citarinostat CM-675 (ACY241) Cat. No.: HY-15994 Cat. No.: HY-114303

Citarinostat (ACY241) is a second generation CM-675 is a dual phosphodiesterase 5 (PDE5) and potent, orally active and high-selective HDAC6 class I histone deacetylases-selective inhibitor, inhibitor with an IC50 of 2.6 nM (IC50s of 35 nM, with IC50 values of 114 nM and 673 nM for PDE5 and 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 HDAC1, respectively. CM-675 has potential to treat and HDAC8, respectively). Citarinostat has Alzheimer’s disease. anticancer effects. Purity: 99.02% Purity: >98% Clinical Data: Phase 1 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 1 mg, 5 mg

Corin CRA-026440 Cat. No.: HY-111048 Cat. No.: HY-19754

Corin is a dual inhibitor of histone lysine CRA-026440 is a potent, broad-spectrum HDAC specific demethylase (LSD1) and histone inhibitor. The Ki values against recombinant HDAC deacetylase (HDAC), with a Ki(inact) of 110 nM isoenzymes HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, for LSD1 and an IC50 of 147 nM for HDAC1. and HDAC10 are 4, 14, 11, 15, 7, and 20 nM respectively.

Purity: 98.75% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

www.MedChemExpress.com 5

Crotonoside CUDC-101 (Isoguanosine) Cat. No.: HY-N0071 Cat. No.: HY-10223

Crotonoside is isolated from Chinese medicinal CUDC-101 is a potent inhibitor of HDAC, EGFR,

herb, Croton. Crotonoside inhibits FLT3 and and HER2 with IC50s of 4.4, 2.4, and 15.7 nM, HDAC3/6, exhibits selective inhibition in acute respectively. myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the treatment of AML. Purity: 98.18% Purity: 99.02% Clinical Data: No Development Reported Clinical Data: Phase 1 Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CXD101 Dacinostat Cat. No.: HY-100748 (NVP-LAQ824; LAQ824) Cat. No.: HY-13606

CXD101 is a potent, selective and orally active Dacinostat is a potent HDAC inhibitor, with an

class I HDAC inhibitor with IC50s of 63 nM, 570 IC50 of 32 nM; Dacinostat also inhibits HDAC1

nM and 550 nM for HDAC1, HDAC2 and HDAC3, with an IC50 of 9 nM, and used in cancer research. respectively. CXD101 has no activity against HDAC class II. CXD101 has antitumor activity.

Purity: 99.14% Purity: 98.45% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 10 mg, 50 mg

Domatinostat Domatinostat tosylate (4SC-202 free base) Cat. No.: HY-16012A (4SC-202) Cat. No.: HY-16012

Domatinostat (4SC-202 free base) is a selective Domatinostat tosylate (4SC-202) is a selective

class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). against Lysine specific demethylase 1 (LSD1).

Purity: 99.08% Purity: 99.66% Clinical Data: Phase 2 Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Droxinostat EDO-S101 (NS 41080) Cat. No.: HY-13267 (Tinostamustine) Cat. No.: HY-101780

Droxinostat(NS41080) is a selective inhibitor of EDO-S101 (Tinostamustine) is a pan HDAC HDAC3, HDAC6, and HDAC8 with IC50 of 16.9, 2.47 inhibitor; inhibits HDAC6, HDAC1, HDAC2 and

and 1.46 μM, respectively; > 8-fold selective HDAC3 with IC50 values of 9 nM, 9 nM and 25 nM, against HDAC3 and no inhibition to HDAC1, 2, 4, 5, respectively. 7, 9, and 10.

Purity: 99.60% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Entinostat Fimepinostat (MS-275; SNDX-275) Cat. No.: HY-12163 (CUDC-907) Cat. No.: HY-13522

Entinostat is an oral and selective class I HDAC Fimepinostat (CUDC-907) potently inhibits class I

inhibitor, with IC50s of 243 nM, 453 nM, and 248 PI3Ks as well as classes I and II HDAC enzymes

nM for HDAC1, HDAC2, and HDAC3, respectively. with an IC50 of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.

Purity: 99.65% Purity: 99.95% Clinical Data: Phase 3 Clinical Data: Phase 2 Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

6 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

FNDR-20123 FNDR-20123 free base Cat. No.: HY-131708A Cat. No.: HY-131708

FNDR-20123 is a safe, first-in-class, and orally FNDR-20123 free base is a safe, first-in-class, active anti-malarial HDAC inhibitor with IC50s of and orally active anti-malarial HDAC inhibitor

31 nM and 3 nM for Plasmodium and human HDAC, with IC50s of 31 nM and 3 nM for Plasmodium and respectively. human HDAC, respectively.

Purity: 98.08% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

FT895 Cat. No.: HY-112285 (ITF-2357) Cat. No.: HY-14842

FT895 is a potent and selective HDAC11 inhibitor Givinostat (ITF-2357) is a HDAC inhibitor with an with an IC50 of 3 nM. IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.

Purity: 99.93% Purity: >98% Clinical Data: No Development Reported Clinical Data: Phase 3 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 1 mg, 5 mg

Givinostat hydrochloride Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride) Cat. No.: HY-14842A (ITF-2357 hydrochloride monohydrate) Cat. No.: HY-14842B

Givinostat (ITF-2357) hydrochloride is a HDAC Givinostat hydrochloride monohydrate (ITF-2357 inhibitor with an IC50 of 198 and 157 nM for hydrochloride monohydrate) is a HDAC inhibitor

HDAC1 and HDAC3, respectively. with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.

Purity: >98% Purity: 97.51% Clinical Data: Phase 3 Clinical Data: Phase 3 Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gnetol HDAC-IN-3 Cat. No.: HY-126052 Cat. No.: HY-19772

Gnetol is a phenolic compound isolated from the HDAC-IN-3 is a histone deacetylase (HDAC) root of Gnetum ula Brongn. Gnetol potently inhibitor, extracted from patent WO/2008040934 A1. inhibits COX-1 (IC50 of 0.78 μM) and HDAC. Target: HDAC. Gnetol is a potent tyrosinase inhibitor with an

IC50 of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Purity: >98% Purity: 98.86% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

HDAC-IN-4 HDAC-IN-5 Cat. No.: HY-128763 Cat. No.: HY-18362

HDAC-IN-4 is a selective HDAC6 and HDAC10 HDAC-IN-5 is a histone deacetylase (HDAC) inhibitor with pIC50s of 7.2 and 6.8 in BRET inhibitor. assay, respectively. Antitumoral activity.

Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

www.MedChemExpress.com 7

HDAC-IN-7 HDAC8-IN-1 (Chidamide impurity) Cat. No.: HY-13592 Cat. No.: HY-111342

HDAC-IN-7 ( impurity) is an impurity of HDAC8-IN-1 is a HDAC8 inhibitor with an IC50 of Chidamide. Chidamide is a potent and orally 27.2 nM. bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.

Purity: >98% Purity: 99.82% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HDACs/mTOR Inhibitor 1 HPOB Cat. No.: HY-114414 Cat. No.: HY-19747

HDACs/mTOR Inhibitor 1 is a dual Histone HPOB is a highly potent and selective inhibitor of

Deacetylases (HDACs) and mammalian target of HDAC6 with an IC50 of 56 nM. HPOB displays >30 Rapamycin (mTOR) target inhibitor for treating fold less potent against other HDACs. HPOB

hematologic malignancies, with IC50s of 0.19 nM, enhances the effectiveness of DNA-damaging 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, anticancer agents in transformed cells but not mTOR and PI3Kα, respectively. normal cells. Purity: 99.12% Purity: ≥95.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IDO1 and HDAC1 Inhibitor ITSA-1 Cat. No.: HY-112147 Cat. No.: HY-100508

IDO1 and HDAC1 Inhibitor (Compound 10) is a dual ITSA-1 is an activator of histone deacetylase

IDO1 and HDAC1 inhibitor with IC50s of 69.0 nM and (HDAC), and counteract 66.5 nM, respectively. (TSA)-induced cell cycle arrest, histone acetylation, and transcriptional activation.

Purity: >98% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

J22352 JAK/HDAC-IN-1 Cat. No.: HY-126147 Cat. No.: HY-126141

J22352 is a PROTAC (proteolysis-targeting JAK/HDAC-IN-1 is a potent JAK2/HDAC dual chimeras)-like and highly selective HDAC6 inhibitor, exhibits antiproliferative and

inhibitor with an IC50 value of 4.7 nM. proapoptotic activities in several hematological

cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively.

Purity: 99.73% Purity: 98.04% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LMK-235 M344 Cat. No.: HY-18998 (D 237; MS 344) Cat. No.: HY-13506

LMK-235 is a potent and selective HDAC4/5 M344 (D 237) is an inhibitor of histone deacetylase

inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, (IC50=100 nM) and an inducer of terminal cell

HDAC2, HDAC11 and HDAC8, with IC50s of 4.22 nM, fifferentiation. 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.

Purity: 99.46% Purity: 99.28% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

8 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Marein MC1568 Cat. No.: HY-N7676 Cat. No.: HY-16914

Marein has the neuroprotective effect due to a MC1568 is a selective class II (IIa) histone reduction of damage to mitochondria function and deacetylas (HDAC II) inhibitor, used for cancer activation of the AMPK signal pathway. research.

Purity: 98.65% Purity: 96.64% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Mocetinostat MPI_5a (MGCD0103) Cat. No.: HY-12164 Cat. No.: HY-113957

Mocetinostat (MGCD0103) is a potent, orally active MPI_5a is a potent and selective HDAC6 inhibitor and isotype-selective HDAC (Class I/IV) inhibitor (IC50=36 nM). MPI_5a weakly inhibits other HDAC with IC50s of 0.15, 0.29, 1.66 and 0.59 μM for isoforms. MPI_5a inhibits acyl-tubulin

HDAC1, HDAC2, HDAC3 and HDAC11, respectively. accumulation in cells with an IC50 value of 210 nM. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8. Purity: 99.43% Purity: ≥99.0% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Size: 5 mg (16.7 mM * 1 mL in Acetonitrile)

MPT0E028 MPT0G211 Cat. No.: HY-124295 Cat. No.: HY-123976

MPT0E028 is an orally active and selective HDAC MPT0G211 is a potent, orally active and selective inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM HDAC6 inhibitor (IC50=0.291nM). MPT0G211 for HDAC1, HDAC2 and HDAC6, respectively. displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 can penetrate the blood-brain barrier.

Purity: >98% Purity: >98% Clinical Data: Phase 1 Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

MPT0G211 mesylate Nampt-IN-3 Cat. No.: HY-123976A Cat. No.: HY-108701

MPT0G211 mesylate is a potent, orally active and Nampt-IN-3 (Compound 35) simultaneously inhibit selective HDAC6 inhibitor (IC50=0.291nM). phosphoribosyltransferase (NAMPT)

MPT0G211 mesylate displays >1000-fold selective and HDAC with IC50s of 31 nM and 55 nM, for HDAC6 over other HDAC isoforms. MPT0G211 respectively. Nampt-IN-3 effectively induces cell mesylate can penetrate the blood-brain barrier. apoptosis and autophagy and ultimately leads to cell death. Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Nanatinostat Nexturastat A (CHR-3996) Cat. No.: HY-13432 Cat. No.: HY-16699

Nanatinostat (CHR-3996) is a potent, class I Nexturastat A is a potent and selective HDAC6 selective and orally active histone deacetylase inhibitor with IC50 of 5 nM; no inhibition on

(HDAC) inhibitor with an IC50 of 8 nM. other HDAC forms.

Purity: 98.02% Purity: 98.49% Clinical Data: Phase 1 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com 9

NKL 22 Oxamflatin Cat. No.: HY-100384 (Metacept-3) Cat. No.: HY-102033

NKL 22 (compound 4b) is a potent and selective Oxamflatin (Metacept-3) is a potent HDAC

inhibitor of histone deacetylases (HDAC), with an inhibitor with an IC50 of 15.7 nM.

IC50 of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 exhibits selectivity over

HDAC2/4/5/7/8 (IC50≥1.59 μM).

Purity: 97.97% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Panobinostat PCI-34051 (LBH589; NVP-LBH589) Cat. No.: HY-10224 Cat. No.: HY-15224

Panobinostat (LBH589; NVP-LBH589) is a potent and PCI-34051 is a potent and selective HDAC8

orally active non-selective HDAC inhibitor, and inhibitor with IC50 of 10 nM, with >200-fold has antineoplastic activities. selectivity over the other HDAC isoforms.

Purity: 99.20% Purity: 99.38% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI3K/HDAC-IN-1 Pimelic Diphenylamide 106 Cat. No.: HY-128582 (RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII) Cat. No.: HY-19348

PI3K/HDAC-IN-1 is a potent dual inhibitor of Pimelic Diphenylamide 106 is a slow, tight-binding PI3K/HDAC, potently inhibits PI3Kδ and HDAC1 with inhibitor of class I HDAC (HDAC 1, 2, and 3, with

IC50s of 8.1 nM and 1.4 nM, respectively. IC50 values of 150 nM , 760nM, and 370 nM, respectively), demonstrating no activity against class II HDACs.

Purity: >98% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pivanex Pomiferin (AN-9; Pivalyloxymethyl butyrate) Cat. No.: HY-120508 (NSC 5113) Cat. No.: HY-N4315

Pivanex (AN-9), a derivative of , is Pomiferin (NSC 5113) acts as an potential

an orally active HDAC inhibitor. Pivanex inhibitor of HDAC, with an IC50 of 1.05 μM, and

down-regulates bcr-abl protein and enhances also potently inhibits mTOR (IC50, 6.2 µM). apoptosis. Pivanex has antimetastic and antiangiogenic properties.

Purity: >98% Purity: 97.36% Clinical Data: Phase 2 Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg, 5 mg

Pracinostat Psammaplin A (SB939) Cat. No.: HY-13322 Cat. No.: HY-N2150

Pracinostat is a potent histone deacetylase (HDAC) Psammaplin A, a marine metabolite, is a potent

inhibitor, with IC50s of 40-140 nM, used for inhibitor of HDAC and DNA methyltransferases. cancer research. Psammaplin A ia a highly potent and selective

DAC1 inhibitor with an IC50 of 0.9 nM.

Purity: 99.07% Purity: >98% Clinical Data: Phase 3 Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 100 μg

10 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

PTACH Pyroxamide (NCH-51) Cat. No.: HY-12954 Cat. No.: HY-13216

PTACH (NCH-51) is a potent HDAC inhibitor with Pyroxamide is a potent inhibitor of histone

IC50s of 48 nM, 32 nM, and 41 nM for HDAC1, deacetylase 1 (HDAC1) with an ID50 of 100 nM. HDAC4, and HDAC6, respectively. PTACH exerts Pyroxamide can induce apoptosis and cell cycle potent growth inhibition against various cancer arrest in leukemia. cells (EC50s of 1.1-9.1 µM) .

Purity: 99.65% Purity: 99.51% Clinical Data: No Development Reported Clinical Data: Phase 1 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

QTX125 Cat. No.: HY-120448 (JNJ-26481585) Cat. No.: HY-15433

QTX125 is a potent and highly selective HDAC6 Quisinostat (JNJ-26481585) is a potent, inhibitor. QTX125 exhibits excellent selectivity second-generation and orally active pan-HDAC over other HDACs. QTX125 has antitumor effects. inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity. Purity: >98% Purity: 98.02% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Quisinostat dihydrochloride Remetinostat (JNJ-26481585 dihydrochloride) Cat. No.: HY-15433A (SHP-141) Cat. No.: HY-100365

Quisinostat dihydrochloride (JNJ-26481585 Remetinostat (SHP-141) is a hydroxamic acid-based dihydrochloride) is an orally available, potent inhibitor of histone deacetylase enzymes (HDAC) pan-HDAC inhibitor with IC50s of 0.11 nM, 0.33 which is under development for the treatment of nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, cutaneous T-cell lymphoma. HDAC2, HDAC4, HDAC10 and HDAC11, respectively.

Purity: >98% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: Phase 2 Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Resminostat hydrochloride (RAS2410; 4SC-201) Cat. No.: HY-14718 (RAS2410 hydrochloride; 4SC-201 hydrochloride) Cat. No.: HY-14718A

Resminostat (RAS2410; 4SC-201) is a potent Resminostat hydrochloride is a potent inhibitor of inhibitor of HDAC1, HDAC3 and HDAC6, with mean HDAC1, HDAC3 and HDAC6, with mean IC50 values

IC50 values of 42.5, 50.1, 71.8 nM, respectively, of 42.5, 50.1, 71.8 nM, respectively, and shows and shows less potent activities against HDAC8, less potent activities against HDAC8, with an IC50 with an IC50 of 877 nM. of 877 nM.

Purity: >98% Purity: 98.11% Clinical Data: Phase 2 Clinical Data: Phase 2 Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

RG2833 RGFP966 (RGFP109) Cat. No.: HY-16425 Cat. No.: HY-13909

RG2833 is a brain-penetrant HDAC inhibitor with RGFP966 is a highly selective HDAC3 inhibitor

IC50s of 60 nM and 50 nM for HDAC1 and HDAC3, with an IC50 of 80 nM and shows no inhibition to respectively. The Ki values for HDAC1 and HDAC3 other HDACs at concentrations up to 15 μM. RGFP966 are 32 and 5 nM, respectively. can penetrate the blood brain barrier (BBB).

Purity: 99.71% Purity: 99.81% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com 11

Ricolinostat (ACY-1215; Rocilinostat) Cat. No.: HY-16026 (FK 228; FR 901228; NSC 630176) Cat. No.: HY-15149

Ricolinostat (ACY-1215) is a potent and selective Romidepsin (FK 228) is a Histone deacetylase

HDAC6 inhibitor, with an IC50 of 5 nM. ACY-1215 (HDAC) inhibitor with anti-tumor activities. also inhibits HDAC1, HDAC2, and HDAC3 with Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4,

IC50s of 58, 48, and 51 nM, respectively. and HDAC6 with IC50s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively.

Purity: 99.87% Purity: 99.98% Clinical Data: Phase 2 Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 1 mg, 5 mg, 10 mg

RTS-V5 Santacruzamate A Cat. No.: HY-112908 (CAY-10683) Cat. No.: HY-N0931

RTS-V5 is a dual HDAC/proteasome inhibitor with Santacruzamate A (CAY-10683) is a potent and

IC50s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, selective HDAC2 inhibitor with an IC50 of 119 pM. HDAC2, HDAC3, HDAC6, HDAC8, respectively.

Purity: >98% Purity: 99.32% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Scriptaid Sinapinic acid (Scriptide; GCK1026) Cat. No.: HY-15489 (Sinapic acid) Cat. No.: HY-W009732

Scriptaid is a potent histone deacetylase (HDAC) Sinapinic acid (Sinapic acid) is a phenolic inhibitor, used in cancer research. Scriptaid is compound isolated from Hydnophytum also a sensitizer to antivirals and has potential formicarum Jack. Rhizome, acts as an inhibitor

for epstein-barr virus (EBV)-associated lymphomas of HDAC, with an IC50 of 2.27 mM, and also treatment. inhibits ACE-I activity.

Purity: 98.59% Purity: 99.61% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 10 mM × 1 mL, 100 mg

SIS17 SKLB-23bb Cat. No.: HY-128918 Cat. No.: HY-18947

SIS17 is a mammalian histone deacetylase 11 (HDAC SKLB-23bb is a potent and selective inhibitor for

11) inhibitor with an IC50 value of 0.83 μM, HDAC6 with an IC50 of 17 nM and shows 25-fold and

inhibits the demyristoylation HDAC11 substrate, 200-fold selectivity relative to HDAC1 (IC50=422

serine hydroxymethyl transferase 2, without nM) and HDAC8 (IC50=3398 nM), respectively. inhibiting other HDACs.

Purity: 98.82% Purity: 98.49% Clinical Data: Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Sodium 4-phenylbutyrate (4-PBA sodium; 4-Phenylbutyric acid Splitomicin sodium; Benzenebutyric acid sodium) Cat. No.: HY-15654 (Splitomycin) Cat. No.: HY-100585

Sodium 4-phenylbutyrate (4-PBA sodium) is an Splitomicin (Splitomycin) is a selective Sir2p inhibitor of HDAC and endoplasmic reticulum (ER) inhibitor. Splitomicin inhibits NAD+-dependent stress, used in cancer and infection research. HDAC activity of Sir2 protein. Splitomicin induces dose-dependent inhibition of HDAC in the yeast

extract with an IC50 of 60 μM.

Purity: 99.80% Purity: 98.42% Clinical Data: Launched Clinical Data: No Development Reported Size: 100 mg, 200 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

12 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

SR-4370 SS-208 Cat. No.: HY-111400 Cat. No.: HY-126330

SR-4370 is an inhibitor of HDAC, with IC50s of SS-208 is a selective HDAC6 inhibitor, with an

0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for IC50 of 12 nM. SS-208 possesses anti-tumor HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, activity in melanoma. respectively.

Purity: 98.03% Purity: 98.13% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) Cat. No.: HY-W009776 Cat. No.: HY-13755

Suberoyl bis-hydroxamic acid (Suberohydroxamic Sulforaphane is an isothiocyanate present acid; SBHA) is a competitive and cell-permeable naturally in widely consumed vegetables.

HDAC1 and HDAC3 inhibitor with ID50 values of Sulforaphane increases tumor suppressor protein 0.25 μM and 0.30 μM, respectively. and inhibits histone deacetylase activity.

Purity: ≥98.0% Purity: 99.75% Clinical Data: No Development Reported Clinical Data: Phase 3 Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg Size: 10 mg, 25 mg, 50 mg, 100 mg

SW-100 Tacedinaline Cat. No.: HY-115475 (N-acetyldinaline; CI-994; Goe-5549) Cat. No.: HY-50934

SW-100, a selective histone deacetylase 6 (HDAC6) Tacedinaline (N-acetyldinaline) is an inhibitor of inhibitor with an IC50 of 2.3 nM, shows at least the histone deacetylase (HDAC) with IC50s of 0.9, 1000-fold selectivity for HDAC6 relative to all 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 other HDAC isozymes. SW-100 displays a respectively. significantly improved ability to cross the blood-brain-barrier. Purity: 99.92% Purity: 99.51% Clinical Data: No Development Reported Clinical Data: Phase 3 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tasquinimod Tefinostat (ABR-215050) Cat. No.: HY-10528 (CHR-2845) Cat. No.: HY-106409

Tasquinimod is an oral antiangiogenic agent, which Tefinostat (CHR-2845) is a has the potential for castration-resistant monocyte/macrophage-targeted pan HDAC inhibitor, prostate cancer treatment. Tasquinimod binds to cleaved into active acid CHR-2847 by the the regulatory Zn2+ binding domain of HDAC4 with intracellular esterase human carboxylesterase-1

Kd of 10-30 nM. Tasquinimod also is a S100A9 (hCE-1). Anti-monocytoid lineage leukaemias inhibitor. activity. Purity: 99.86% Purity: 98.08% Clinical Data: Phase 3 Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TH34 TMP195 Cat. No.: HY-111818 Cat. No.: HY-18361

TH34, an HDAC6/8/10 inhibitor with IC50s of 4.6 TMP195 is a selective class IIa histone

μM, 1.9 μM, and 7.7 μM respectively, shows high deacetylase (HDAC) inhibitor with Kis of 59, 60, selectivity over HDAC1/2/3. 26, 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

Purity: 99.05% Purity: 99.68% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com 13

TMP269 Trichostatin A Cat. No.: HY-18360 (TSA) Cat. No.: HY-15144

TMP269 is a novel and selective class IIa histone Trichostatin A (TSA) is a potent and specific

deacetylase (HDAC) inhibitor with IC50s of 157 inhibitor of HDAC class I/II, with an IC50 value nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 of 1.8 nM for HDAC. and HDAC9, respectively.

Purity: 98.74% Purity: 99.53% Clinical Data: No Development Reported Clinical Data: Phase 1 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Triciferol Tubacin Cat. No.: HY-131961 Cat. No.: HY-13428

Triciferol functions as a multiple ligand with Tubacin is a potent and selective inhibitor of

combined VDR agonist and HDAC antagonist HDAC6, with an IC50 value of 4 nM and activities. Triciferol binds directly to the VDR approximately 350-fold selectivity over HDAC1.

(IC50=87 nM), and functions as an agonist with 1,25D-like potency on several 1,25D target genes.

Purity: 98.61% Purity: 99.17% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

Tubastatin A Tubastatin A Hydrochloride Cat. No.: HY-13271A (Tubastatin A HCl; TSA HCl) Cat. No.: HY-13271

Tubastatin A is a potent and Tubastatin A (Hydrochloride) is a potent and selective HDAC6 inhibitor with an selective HDAC6 inhibitor

IC50 of 15 nM in a cell-free assay, and is with IC50 of 15 nM in a cell-free selective (1000-fold more) against all other assay, and is selective (1000-fold more) against isozymes except HDAC8 (57-fold more). all other isozymes except HDAC8 (57-fold more).

Purity: 98.12% Purity: 98.31% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Tucidinostat Tucidinostat D4 (Chidamide; HBI-8000; CS 055) Cat. No.: HY-109015 (Chidamide D4; HBI-8000 D4; CS 055 D4) Cat. No.: HY-109015S

Tucidinostat (Chidamide) is a potent and orally Tucidinostat D4 (Chidamide D4) is the deuterium bioavailable HDAC enzymes class I (HDAC1/2/3) labeled Tucidinostat. Tucidinostat is a potent and

and class IIb (HDAC10) inhibitor, with IC50s of orally bioavailable HDAC enzymes class I 95, 160, 67 and 78 nM, less active on HDAC8 and (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with

HDAC11 (IC50s, 733 nM, 432 nM, respectively), and IC50s of 95, 160, 67 and 78 nM, respectively. shows no effect on HDAC4/5/6/7/9. Purity: ≥98.0% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Size: 1 mg, 5 mg

UF010 Valproic acid Cat. No.: HY-18976 (VPA; 2-Propylpentanoic Acid) Cat. No.: HY-10585

UF010 is a potent and selective HDAC inhibitor Valproic acid (VPA; 2-Propylpentanoic Acid) is an

with IC50 ~0.06 μM, 0.1 μM, 0.5 μM and 1.5 μM for HDAC inhibitor, with IC50 in the range of 0.5 and

HDACs 3, 2, 1 and 8, respectively. It has > 2 mM, also inhibits HDAC1 (IC50, 400 μM), and 6-fold selectivity over other HDACs. induces proteasomal degradation of HDAC2.

Purity: 99.08% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 25 g

14 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected]

Valproic acid sodium salt (Sodium ) Cat. No.: HY-10585A (SAHA; Suberoylanilide hydroxamic acid) Cat. No.: HY-10221

Valproic acid sodium salt (Sodium Valproate) is an Vorinostat (SAHA) is a potent and orally active

HDAC inhibitor, with IC50 in the range of 0.5 and pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class

2 mM, also inhibits HDAC1 (IC50, 400 μM), and I), HDAC7 (Class II) and HDAC11 (Class IV), with induces proteasomal degradation of HDAC2. ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis. Purity: ≥98.0% Purity: 99.90% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 25 g Size: 10 mM × 1 mL, 250 mg, 500 mg, 1 g, 5 g

WT-161 Cat. No.: HY-100871

WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM.

Purity: 98.52% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

www.MedChemExpress.com 15